Search hospitals > California > Redwood City
Kaiser Permanente-Redwood City
Claim this profileRedwood City, California 94063
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
Conducts research for Adenocarcinoma
159 reported clinical trials
7 medical researchers
Summary
Kaiser Permanente-Redwood City is a medical facility located in Redwood City, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Adenocarcinoma and other specialties. Kaiser Permanente-Redwood City is involved with conducting 159 clinical trials across 305 conditions. There are 7 research doctors associated with this hospital, such as Jennifer M. Suga, Samantha A. Seaward, Tatjana Kolevska, MD, and Ramey D. Littell.Area of expertise
1Cancer
Global LeaderStage II
Stage III
Stage IV
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Jennifer M. SugaKaiser Permanente-Oakland1 year of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
34 reported clinical trials
98 drugs studied
Samantha A. SeawardKaiser Permanente Medical Center - Santa Clara2 years of reported clinical research
Studies Cancer
Studies Breast Cancer
22 reported clinical trials
63 drugs studied
Tatjana Kolevska, MDKaiser Permanente-Vallejo7 years of reported clinical research
Studies Skin Cancer
Studies Melanoma
21 reported clinical trials
51 drugs studied
Ramey D. LittellKaiser Permanente-Roseville4 years of reported clinical research
Studies Ovarian Cancer
Studies Adenocarcinoma
5 reported clinical trials
13 drugs studied
Clinical Trials running at Kaiser Permanente-Redwood City
Non-Small Cell Lung Cancer
Lung Cancer
Ovarian Cancer
Prostate Cancer
Fallopian Tube Cancer
Pancreatic Cancer
Cancer
Breast Cancer
Peritoneal Cancer
Meningioma
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Kaiser Permanente-Redwood City?
Kaiser Permanente-Redwood City is a medical facility located in Redwood City, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Adenocarcinoma and other specialties. Kaiser Permanente-Redwood City is involved with conducting 159 clinical trials across 305 conditions. There are 7 research doctors associated with this hospital, such as Jennifer M. Suga, Samantha A. Seaward, Tatjana Kolevska, MD, and Ramey D. Littell.